Pathogenesis and treatment of ANCA-associated systemic vasculitis

Journal of the Royal Society of Medicine

Volumn 92, Issue 9, 1999, Pages 456-461

  Salama, A D ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; THYMOCYTE ANTIBODY;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ENDOTHELIUM CELL; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; NEUTROPHIL; ORAL DRUG ADMINISTRATION; PLASMAPHERESIS; REVIEW; SYSTEMIC VASCULITIS; T LYMPHOCYTE;

EID: 0032869953     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1177/014107689909200906     Document Type: Review

References (40)

1. Pusey CD. Vasculitis and rapidly progressive glomerulonephritis. In: Savill J. ed. Horizons In Medicine, Vol. 9 London; Royal College of Physicians of London, 1998:85-94
2. Savage COS, Harper L, Adu D. Primary systemic vasculitis. Lancet 1997;349:553-8
3. Jennette JC, Falk RJ, Andrassy K, et al Nomonclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92
4. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997;337:1512-23
5. Ewert BH, Jennette JC, Falk RJ. The pathogenic role of antineutrophil cytoplasmic autoantibodies. Am J Kidney Dis 1991;18:188-95
6. Charles LA, Caldas ML, Falk RJ, Terrell RS, Jennette JC. Antibodies against granule proteins activate neutrophils in vitro. J Leukoc Biol 1991;50:539-46
7. Reumas D, Vossebeld PJ, Roos D, Verhoeven AJ. Effect of tumor necrosis factor induced integrin activation on Fc gamma receptor II-mediated signal transduction: relevance for activation of neutrophils by anti proteinase 3 or anti myeloperoxidase antibodies. Blood 1995;86: 3189-95
8. Gilligan HM, Bredy B, Brady HR, et al. Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apuptotic neutrophils in the absence of neutrophil priming. J Exp Med 1996;184:2231-41
9. Savage CO, Gaskin G, Pusey CO, Pearson JD. Anti-neutrophil cytoplasm antibodies can recognize vascular endothelial cell-bound anti-neutrophil cytoplasm antibody-associated autoantigens. Exp Nephrol 1993;1:190-5
10. Sibelius U, Hattar K, Schenkel A, et al. Wegener's granulomatosis: anti-proteinase 3 antibodies are potent inductors of human endothelial cell signaling and leakage response. J Esp Med 1998;187:497-503
11. Dolman KM, van de Wiel BA, Kam CM, et al. Proteinase 3: substrate specificity and possible pathogenetic effect of Wegener's granulomatosis autoantibodies (c ANCA) by dysregulation of the enzyme. Adv Exp Med Bio 1993;336:55-60
12. Esnault VL, Testa A, Audrain M, et al. Alpha 1 antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int 1993;43-1329-32
13. Griffith ME, Lovegrove JU, Gaskin G, Whitehouse DB, Pusey CD. C-antineutrophil cytoplasmic antibody positivity in vasailitis patients is associated with the Z allele of alpha 1-antitrypsin, and P-antineutrophil cytoplasmic antibody positivity with the S allele. Nephrol Dial Transplant 1996;11:438-43
14. Gaskin G, Pusey CD. Clinical aspects of systemic vasculitis. In: Pusey CD, Rees AJ, eds. Rapidly Progressive Glomerulonephritis. Oxford: Oxford University Press, 1998:125-48
15. Gaskin G, Savage CO, Ryan JJ, et al. Anti-neutrophil cytoplasmic: antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant 1991;6:689-94
16. Jayne DR, Gaskin G, Pusey CD, Lockwood CM. ANCA and predicting relapse in systemic vasculitis. Quarr J Med 1995;88:127-33
17. De'Oliviera J, Gaskin G, Dash A, Rees AJ, Pusey CD. Relationship between disease activity and anti neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis 1995;25:380-9
18. Tervaert JWC, Holtema MG, Hene RW, et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990;336:709-11
19. Dolman KM, Gans RO, Vervaat TJ, et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 1991;342:651-2
20. Vogt BA, Kim Y, Jennette JC, Falk RJ, Burke BA, Sinaiko A. Antineutrophil cytoplasmic autoantibody positive crescentic glomerulonephritis as a complication of treatment with propylthiouracil in children. J Pediatr 1994;124:986-8
21. D'Cruz D, Chesser AM, Lightowler C, et al. Antineutrophil cytoplamic antibody-positive crescentic glomerulonephritis associated with anti-thyroid drug treatment, Br J Rheumatol 1995;34:1090-1
22. Heeringa P, Brouwer E, Coben Tervaert JW, Weening JJ, Kallenberg CG. Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis. Kidney Int 1998;53:253-63
23. Griffith MR, Pusey CD. HLA genes in ANCA-associated vasculitides. Exp Clin. Immunogener 1997;14:196-205
24. Griffith ME, Coulthart A, Pusey CD. T cell responses to mycloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis. Clin Exp Immunol 1996;103:253-8
25. Giscombe R, Grunewald J, Nityanand S, Lefvert AK. T cell receptor (TCR) V gene usage in patients with systemic necrotizing vasculitis. Clin Exp Immunol 1995;101:213-19
26. Simpson IJ, Skinner MA, Geursen A, et al Peripheral blood T lymphocytes in systemic vasculitis: increased T cell receptor V beta 2 gene usage in microscopic polyarteritis. Clin Clin Exp Immunol 1995;101:220-6
27. Stegeman CA, Cohen Tervaert JW, Huiterna MG, Kallenberg CG. Serum markers of T cell activation in relapses of Wegener's granulomatosis. Clin Exp Immunol 1993;91:415-20
28. 4+T cells exhibiting an unbalanced Tn1-typi- T cell cytokine pattern: reversal with IL-10. J Immunol 1998; 160:3602-9
29. Schmitt WH, Heesen C, Csernok E, Rautmann A, Gross WL. Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity, Arthritis Rheum 1992;35:1088-96
30. Pinching AJ, Rees AJ, Pussell BA, Lockwood CM, Mitchison RS, Peters DK. Relapses in Wegener's granulomatosis: the role of infection. BMJ 1980;281:836-8
31. Sitara D, Hoffbrand D. Chronic bronchial suppuration and antineutrophil cytoplasmic antibody (ANCA) positive systemic vasculitis. Postgrad Med J 1990;66:669-71
32. Stegeman CA, cohen Tervaert JW, Kallenberg CG. Anti-neutrophil cytoplasmic antibodies: tools for diagnosis and follow up in systemic vasculitis. Ann Méd Interne Paris 1994;145:523-32
33. Stegeman CA, Cohen Tervaert JW, de Jong PL, Kallenberg CG. Trimethoprim sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N: Engl J Med 1996;335-16-20
34. Fauci A.S, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983;98:76-85
35. Jayne DR, Tasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 1997;72:737-47
36. Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies, Kidney Int 1991;40:757-63
37. Jayne DRW, Davies MJ, Fox CJ, Black CM. Treatment of systemic vasculitis with pooled Intravenous immunoglobulin. Lancet 1991;337:1137-9
38. Lockwood CM, Thiru S, Stewart S, et al. Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. Quart J Med 1996;89:903-12
39. Exley AR, Carruthers DM, Luqmani RA, et al. Damage occurs early in systemic vasculitis and is an index of outcome. Quart J Med 1997;90:391-9
40. Allen A, Pusey CD, Gaskin G. Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody - associated systemic vasculitis. J Am to Nephrol 1998;9:1258-63